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Is Otilonium Bromide Really Effective for Treating 
Asian Patients With Irritable Bowel Syndrome?: 
Author’s Reply
TO THE EDITOR: We do appreciate Dr. Kim for his interest 
and comments
1 on our publication.
2 Mebeverine has long been 
an effective antispasmodic to treat the main symptoms of irritable 
bowel syndrome (IBS). Dr. Kim is correct that most IBS trials 
have employed mebeverine in the conventional dose of 135 mg 
t.i.d., which is commonly used and studied among the Korean 
IBS patients.
3 For the purposes of relieving IBS abdominal pain 
and global improvement, a meta-analysis indicates no difference 
between the slow releasing compound with dose of 200 mg b.i.d. 
and conventional dose of 135 mg t.i.d.
4 However, mebeverine 
100 mg tablet t.i.d. is also available in the market including 
Taiwan and we had studied this dosage in comparison with a cal-
cium channel blocker.
5,6 In fact, mebeverine 100 mg tablet has 
been marketed and popularly used in our country for decades 
with a faithful credit. This is why we employed mebeverine 100 
mg tablet t.i.d. as the active-controlled agent when the otilonium 
bromide (OB) study was designed. It is unknown whether this 
lower dose preparation would exhibit an inferior efficacy com-
pared to the conventional 135 mg tablet used in other countries. 
With regard to the impact of IBS subgroups on the mebeverine 
efficacy, he suggested that diarrhea-predominant IBS patients 
might be treated more effectively.
1 Because mebeverine is recom-
mended to treat IBS main symptoms despite of the characteristic 
stool consistency,
4,5 we never tried to confirm the subgroup effect. 
Interestingly, a recent large-scale European multi-national study 
indicated that OB was safe, well tolerated and superior to placebo 
in reducing the frequency of abdominal pain, severity of abdomi-
nal bloating and even prevented IBS symptom relapse, and this 
study further addressed that IBS subgroups did not exhibit any 
obvious impact on OB therapy.
7 As our study already depicted 
that OB exhibits a efficacy comparable to mebeverine,
2 we do not 
expect that the IBS subgroups may have a definite impact on 2 
studied agents.
The third concern is that almost all our enrolled IBS patients 
had used rescue agents to treat their troublesome bowel move-
ment (BM) disorders in terms of constipation and diarrhea when 
the study was conducted. Apart from the main IBS symptoms, 
IBS subjects are also very concerned about their disordered BM.
8 
If an IBS study does not include the rescue agents for the events 
of intractable diarrhea or constipation, many of them may violate 
protocol, which would lead to the study failure. Unfortunately, 
almost all our patients had consumed rescue agents during the 
trial, which probably means that they might have recorded a bet-
ter satisfied score on the BM. We recognized that this BM issue 
has become the concern of investigators, whereas the satisfied re-
sponse of recorded BM was mostly unreliable. Finally, we do ex-
pect that our response has resolved the controversy suggested by 
Dr. Kim.
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